Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 106
Filter
1.
Eur J Med Res ; 28(1): 19, 2023 Jan 11.
Article in English | MEDLINE | ID: mdl-36631838

ABSTRACT

BACKGROUND: Currently we do not have an ideal biomarker in lupus nephritis (LN) that should help us to identify those patients with SLE at risk of developing LN or to determine those patients at risk of renal progression. We aimed to evaluate the development of a prognostic index for LN, through the evaluation of clinical, analytical and histological factors used in a cohort of lupus. We have proposed to determine which factors, 6 months after the diagnosis of LN, could help us to define which patients will have a worse evolution of the disease and may be, more aggressive treatment and closer follow-up. METHODS: A retrospective study to identify prognostic factors was carried out. We have included patients over 18 years of age with a clinical diagnosis of systemic lupus erythematosus (SLE) and kidney involvement confirmed by biopsy, who are followed up in our centre during the last 20 years. A multi-step statistical approach will be used in order to obtain a limited set of parameters, optimally selected and weighted, that show a satisfactory ability to discriminate between patients with different levels of prognosis. RESULTS: We analysed 92 patients with LN, although only 73 have been able to be classified according to whether or not they have presented poor renal evolution. The age of onset (44 vs. 32; p = 0.024), the value of serum creatinine (1.41 vs. 1.04; p = 0.041), greater frequency of thrombocytopenia (30 vs. 7%; p = 0.038), higher score in the renal chronicity index (2.47 vs. 1.04; p = 0.015), proliferative histological type (100%) and higher frequency of interstitial fibrosis (67 vs. 32%; p = 0.017) and tubular atrophy (67 vs. 32%; p = 0.018) was observed between two groups. The multivariate analysis allowed us to select the best predictive model for poor outcome at 6 months based on different adjustment and discrimination parameters. CONCLUSION: We have developed a prognostic index of poor renal evolution in patients with LN that combines demographic, clinical, analytical and histopathological factors, easy to use in routine clinical practice and that could be an effective tool in the early detection and management.


Subject(s)
Lupus Erythematosus, Systemic , Lupus Nephritis , Humans , Adolescent , Adult , Lupus Nephritis/diagnosis , Prognosis , Retrospective Studies , Kidney/pathology
2.
Ann Hum Genet ; 85(6): 245-248, 2021 11.
Article in English | MEDLINE | ID: mdl-33830497

ABSTRACT

Population stratification (PS) is a confounding factor in genome-wide association studies (GWASs) and also an interesting process itself. Latin American populations have mixed genetic ancestry, which may account for PS. We have analyzed the relatedness, by means of the identity-by-descent (IBD) estimations, in a sample of 1805 individuals and 1.006.703 autosomal mutations from a case-control study of colorectal cancer in Mexico. When using the recommended protocol for quality control assessment, 402 should have been removed due to relatedness. Our purpose was to analyze this value in the context of an admixed population. For that aim, we reanalyzed the sample using two software designed for admixed populations, obtaining estimates of 110 and 70 related individuals to remove. The results showed that the first estimation of relatedness was an effect of the higher Native American contribution in part of the data samples, being a confounding factor for IBD estimations. We conclude in the importance of considering PS and genetic ancestry in order to avoid spurious results, not only in GWAS but also in relatedness analysis.


Subject(s)
Colorectal Neoplasms/genetics , Genetics, Population , Genome-Wide Association Study , Case-Control Studies , Hispanic or Latino/genetics , Humans , Mexico , Software , American Indian or Alaska Native/genetics
3.
Physiotherapy ; 108: 37-44, 2020 09.
Article in English | MEDLINE | ID: mdl-32707289

ABSTRACT

OBJECTIVES: To test the effect of a structured abdominal hypopressive technique (AHT) programme on pelvic floor muscle (PFM) tone and urinary incontinence (UI) in women. DESIGN: Crossover trial with random assignment of women to one of two groups: Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT). SETTING: Two cultural centres in Madrid, Spain. PARTICIPANTS: Women aged 20-65 years. INTERVENTIONS: Two months of supervised AHT exercises compared with 2 months of rest. MAIN OUTCOME MEASURES: Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)]. RESULTS: Forty-two women were randomised to two groups (both n=21). No sequence or period effect was noted. The mean difference in PFM tone after the 2-month AHT programme was 59g/cm² [95% confidence interval (CI) 37 to 82]; the between-group difference was 83g/cm² (95% CI 50 to 116; P<0.001). After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001). The majority of participants reported improved body image and sense of well-being. CONCLUSIONS: A structured 2-month AHT programme for women showed short-term benefits in PFM tone and UI. In addition, study participants reported improved body image and sense of well-being, and programme satisfaction, as demonstrated by questionnaire at the end of the intervention period. Further research is needed to test the long-term effects and effectiveness of AHT compared with other PFM exercises. ClinicalTrials.gov Identifier NCT0221241.


Subject(s)
Exercise Therapy/methods , Muscle Tonus/physiology , Pelvic Floor/physiopathology , Urinary Incontinence/physiopathology , Urinary Incontinence/therapy , Adult , Aged , Cross-Over Studies , Female , Humans , Middle Aged , Surveys and Questionnaires , Young Adult
4.
Scand J Rheumatol ; 48(1): 42-51, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30039730

ABSTRACT

OBJECTIVE: The aim of this study was to analyse differences in clinical presentation in patients with early (< 3 years' duration) systemic sclerosis (SSc), comparing three age groups according to disease subsets. METHOD: Cross-sectional analysis of the prospective EULAR Scleroderma Trials and Research database (EUSTAR) was performed. Patients fulfilling preliminary American College of Rheumatology 1980 classification criteria for SSc, with < 3 years from the first non-Raynaud's SSc symptom at first entry, were selected. Patients with < 3 years from the first SSc symptom, including Raynaud's phenomenon, were also analysed. SSc-related variables, including antibodies, SSc subsets, and organ involvement, were examined. Age was categorized into ≤ 30, 31-59, and ≥ 60 years. We performed descriptive and bivariate analyses. RESULTS: The study included 1027 patients: 90% Caucasian, 80% women, and 40% with diffuse disease. In early stages of SSc, younger patients had significantly more anti-Scl-70 antibodies and diffuse disease. With increasing age, we observed more elevation of estimated pulmonary systolic pressure on echocardiography (5%, 13%, and 30%, respectively, in the three age groups), cardiac conduction blocks (6%, 6%, and 15%), and left ventricular diastolic dysfunction (4%, 12%, and 27%). The results were similar for 650 patients with < 3 years from first SSc symptom, including Raynaud's. CONCLUSION: In early stages of SSc, older patients showed data indicating more severe disease with greater cardiac involvement. The diffuse subset was more frequent in the younger subgroup. The identification of such differences may help in selecting appropriate management for individual patients in clinical practice.


Subject(s)
Registries , Scleroderma, Systemic/epidemiology , Adult , Age Distribution , Age Factors , Age of Onset , Cross-Sectional Studies , Databases, Factual , Europe/epidemiology , Female , Humans , Incidence , Male , Middle Aged , Prevalence , Retrospective Studies , Scleroderma, Systemic/diagnosis , Sex Distribution
5.
Food Chem ; 277: 75-83, 2019 Mar 30.
Article in English | MEDLINE | ID: mdl-30502212

ABSTRACT

A protein analysis in the pulp of Moro blood oranges (Citrus sinensis L. Osbeck) at the onset and after 30 days of storage at either 4 or 9 °C was performed. All differential proteins belonged to different functional classes (sugar, amino acid and secondary metabolism, defense, stress response, oxidative process, transport and cellular component biogenesis), displaying a differential accumulation in those Moro oranges kept at 9 versus 4 °C, and in those stored at 4 °C versus onset. Anthocyanin biosynthesis structural proteins chalcone synthases and flavonone 3-hydroxylase and different glutathione S-transferases related with their vacuolar transport were up-accumulated in fruits kept at 9 versus 4 °C and versus the onset. Proteins related with defense and oxidative stress displayed a similar pattern, concomitant with a higher anthocyanin content, denoting a possible role of defense and other stress response pathways in anthocyanin production/accumulation.


Subject(s)
Citrus sinensis/metabolism , Cold Temperature , Food Storage , Plant Proteins/metabolism , Anthocyanins/metabolism , Color , Fruit/metabolism , Oxidative Stress
6.
Actas dermo-sifiliogr. (Ed. impr.) ; 109(2): 155-161, mar. 2018. ilus, tab
Article in Spanish | IBECS | ID: ibc-172388

ABSTRACT

INTRODUCCIÓN Y OBJETIVO: Las malformaciones capilares son las malformaciones vasculares más frecuentes en la infancia. El tratamiento de elección sigue siendo el láser de colorante pulsado (LCP), sin embargo, la resolución completa con este habitualmente no se consigue, motivo por el que se siguen buscando otras alternativas terapéuticas. En este estudio comunicamos nuestra experiencia con el láser dual secuencial de LCP y Nd:YAG. MATERIAL Y MÉTODOS: Se efectuó un estudio retrospectivo y descriptivo de los pacientes con malformaciones capilares tratados con el láser dual de LCP y Nd:YAG desde 2006 hasta 2011. Cuatro dermatólogos valoraron el grado de eficacia en una escala del 10 al 0. Se analizó la posibilidad de factores predictores de mejor respuesta al tratamiento: sexo, color de la lesión, existencia de hipertrofia asociada y tamaño de la malformación. Se recogieron igualmente los efectos secundarios. RESULTADOS: Se incluyeron 71 pacientes, presentando el conjunto de ellos una mejoría estadísticamente significativa tras el tratamiento. Las malformaciones de coloración violácea que tenían hipertrofia asociada y las de menor tamaño se asociaron con una mejor respuesta. Se produjeron efectos adversos en un 26,76% de los pacientes, siendo la presencia de zonas atróficas puntuales el más frecuente. CONCLUSIONES: Consideramos que el láser dual de LCP y Nd:YAG es una alternativa eficaz para el tratamiento de malformaciones capilares en paciente seleccionados


INTRODUCTION AND OBJECTIVE: Capillary malformations are the most common vascular malformations in childhood. The current treatment of choice is pulsed dye laser (PDL) therapy, but this frequently does not result in complete resolution. The search for alternative treatment strategies thus continues. In this study we describe our experience with the use of sequential dual-wavelength PDL and Nd:YAG laser therapy in patients with capillary malformations. MATERIAL AND METHODS: We conducted a retrospective, descriptive study of patients with capillary malformations treated with dual-wavelength PDL and Nd:YAG laser therapy between 2006 and 2011. Four dermatologists rated the effectiveness of treatment on a scale of 10 to 0. We also investigated the potential value of the following factors as predictors of better treatment response: sex, malformation size and color, and presence of associated hypertrophy. Adverse effects were also analyzed. RESULTS: We studied 71 patients and most of them experienced a statistically significant improvement after treatment. More favorable responses were observed for violaceous malformations, lesions with associated hypertrophy, and smaller lesions. Adverse effects were reported for 26.76% of patients, and the most common effect was the appearance of isolated areas of skin atrophy. CONCLUSIONS: We consider that sequential dual-wavelength PDL and ND:YAG laser therapy is an effective alternative for treating capillary malformations in selected patients


Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Adult , Aged , Vascular Malformations/diagnosis , Vascular Malformations/drug therapy , Vascular Malformations/therapy , Capillaries/injuries , Vascular Malformations/complications , Vascular Malformations/prevention & control , Capillaries/pathology , Lasers
7.
Actas Dermosifiliogr (Engl Ed) ; 109(2): 155-161, 2018 Mar.
Article in English, Spanish | MEDLINE | ID: mdl-29183621

ABSTRACT

INTRODUCTION AND OBJECTIVE: Capillary malformations are the most common vascular malformations in childhood. The current treatment of choice is pulsed dye laser (PDL) therapy, but this frequently does not result in complete resolution. The search for alternative treatment strategies thus continues. In this study we describe our experience with the use of sequential dual-wavelength PDL and Nd:YAG laser therapy in patients with capillary malformations. MATERIAL AND METHODS: We conducted a retrospective, descriptive study of patients with capillary malformations treated with dual-wavelength PDL and Nd:YAG laser therapy between 2006 and 2011. Four dermatologists rated the effectiveness of treatment on a scale of 10 to 0. We also investigated the potential value of the following factors as predictors of better treatment response: sex, malformation size and color, and presence of associated hypertrophy. Adverse effects were also analyzed. RESULTS: We studied 71 patients and most of them experienced a statistically significant improvement after treatment. More favorable responses were observed for violaceous malformations, lesions with associated hypertrophy, and smaller lesions. Adverse effects were reported for 26.76% of patients, and the most common effect was the appearance of isolated areas of skin atrophy. CONCLUSIONS: We consider that sequential dual-wavelength PDL and ND:YAG laser therapy is an effective alternative for treating capillary malformations in selected patients.


Subject(s)
Capillaries/abnormalities , Lasers, Dye/therapeutic use , Lasers, Solid-State/therapeutic use , Vascular Malformations/surgery , Adolescent , Adult , Aged , Capillaries/surgery , Child , Female , Humans , Male , Middle Aged , Retrospective Studies , Vascular Surgical Procedures/methods , Young Adult
8.
Ann Rheum Dis ; 76(1): 126-132, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27190098

ABSTRACT

OBJECTIVE: To compare the value that rheumatologists across Europe attach to patients' preferences and economic aspects when choosing treatments for patients with rheumatoid arthritis. METHODS: In a discrete choice experiment, European rheumatologists chose between two hypothetical drug treatments for a patient with moderate disease activity. Treatments differed in five attributes: efficacy (improvement and achieved state on disease activity), safety (probability of serious adverse events), patient's preference (level of agreement), medication costs and cost-effectiveness (incremental cost-effectiveness ratio (ICER)). A Bayesian efficient design defined 14 choice sets, and a random parameter logit model was used to estimate relative preferences for rheumatologists across countries. Cluster analyses and latent class models were applied to understand preference patterns across countries and among individual rheumatologists. RESULTS: Responses of 559 rheumatologists from 12 European countries were included in the analysis (49% females, mean age 48 years). In all countries, efficacy dominated treatment decisions followed by economic considerations and patients' preferences. Across countries, rheumatologists avoided selecting a treatment that patients disliked. Latent class models revealed four respondent profiles: one traded off all attributes except safety, and the remaining three classes disregarded ICER. Among individual rheumatologists, 57% disregarded ICER and these were more likely from Italy, Romania, Portugal or France, whereas 43% disregarded uncommon/rare side effects and were more likely from Belgium, Germany, Hungary, the Netherlands, Norway, Spain, Sweden or UK. CONCLUSIONS: Overall, European rheumatologists are willing to trade between treatment efficacy, patients' treatment preferences and economic considerations. However, the degree of trade-off differs between countries and among individuals.


Subject(s)
Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Choice Behavior , Patient Preference , Rheumatologists/psychology , Adult , Antirheumatic Agents/adverse effects , Cost-Benefit Analysis , Europe , Female , Humans , Male , Middle Aged , Practice Patterns, Physicians' , Surveys and Questionnaires
9.
Lupus ; 24(11): 1135-42, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25813871

ABSTRACT

OBJECTIVE: Obstetric complications are common in patients with antiphospholipid syndrome. However, the impact of antiphosholipid antibodies (aPL) in the pregnancy outcomes of asymptomatic aPL carriers is uncertain. The aim of this systematic review is to assess whether primary prophylaxis is beneficial to prevent obstetric complications during pregnancy in asymptomatic women positive for aPL who have no history of recurrent pregnancy loss or intrauterine fetal death. METHODS: Studies evaluating the effect of prophylactic treatment versus no treatment in asymptomatic pregnant aPL carriers were identified in an electronic database search. Design, population and outcome homogeneity of studies was assessed and meta-analysis was performed. The pooled Mantel-Haenszel relative risk of specific pregnancy outcomes was obtained using random effects models. Heterogeneity was measured with the I(2) statistic. All analyses were conducted using Review Manager 5.3. RESULTS: Data from five studies involving 154 pregnancies were included and three studies were meta-analysed. The risk ratio and 95% confidence interval (CI) of live birth rates, preterm birth, low birth weight and overall pregnancy complications in treated and untreated pregnancies were 1.14 (0.18-7.31); 1.71 (0.32-8.98); 0.98 (0.07-13.54) and 2.15 (0.63-7.33),respectively. Results from the meta-analysis revealed that prophylactic treatment with aspirin is not superior to placebo to prevent pregnancy complications in asymptomatic aPL carriers. CONCLUSION: This systematic review did not find evidence of the superiority of prophylactic treatment with aspirin compared to placebo or usual care to prevent unfavourable obstetric outcomes in otherwise healthy women with aPL during the first pregnancy.


Subject(s)
Antibodies, Anticardiolipin/immunology , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/physiopathology , Pregnancy Complications/prevention & control , Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/immunology , Female , Humans , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/immunology , Pregnancy Outcome , Primary Prevention/methods
10.
Clin Exp Rheumatol ; 33(6): 910-6, 2015.
Article in English | MEDLINE | ID: mdl-25797345

ABSTRACT

OBJECTIVES: Patient reported outcomes (PROs) are relevant in rheumatology. Variable accessibility and validity of commonly used PROs are obstacles to homogeneity in evidence synthesis. The objective of this project was to provide a comprehensive library of "validated PROs". METHODS: A launch meeting with rheumatologists, PROs methodological experts, and patients, was held to define the library's aims and scope, and basic requirements. To feed the library we performed systematic reviews on selected diseases and domains. Relevant information on PROs was collected using standardised data collection forms based on the COSMIN checklist. RESULTS: The EULAR Outcomes Measures Library (OML), whose aims are to provide and to advise on PROs on a user-friendly manner albeit based on scientific grounds, has been launched and made accessible to all. PROs currently included cover any domain and, are generic or specifically target to the following diseases: rheumatoid arthritis, osteoarthritis, spondyloarthritis, low back pain, systemic lupus erythematosus, gout, osteoporosis, juvenile idiopathic arthritis, and fibromyalgia. Up to 236 instruments (106 generic and 130 specific) have been identified, evaluated, and included. The systematic review for SLE, which yielded 10 specific instruments, is presented here as an example. The OML website includes, for each PRO, information on the construct being measured and the extent of validation, recommendations for use, and available versions; it also contains a glossary on common validation terms. CONCLUSIONS: The OML is an in progress library led by rheumatologists, related professionals and patients, that will help to better understand and apply PROs in rheumatic and musculoskeletal diseases.


Subject(s)
Lupus Erythematosus, Systemic , Outcome and Process Assessment, Health Care/standards , Patient Care Management , Evidence-Based Practice , Humans , Library Collection Development , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy , Patient Care Management/methods , Patient Care Management/standards , Reproducibility of Results
11.
Antonie Van Leeuwenhoek ; 107(5): 1217-23, 2015 May.
Article in English | MEDLINE | ID: mdl-25731740

ABSTRACT

Brettanomyces bruxellensis is the main microorganism responsible for the production of off-flavours in wine. Studies have been carried out in synthetic cultures using p-coumaric acid for the production of vinyl and ethylphenols. The results obtained have been extrapolated to authentic wine, but there is no evidence that this correlation will be correct. We studied the behaviour of B. bruxellensis native strain LAMAP L2480 in authentic wine and in a synthetic medium with a chemical composition similar to the authentic wine used in this study (basal synthetic wine + pH, ethanol and hydroxycinnamic acid concentrations of commercial wine). In some assays, B. bruxellensis has been studied using media containing 100 mg L(-1) p-coumaric acid, so we also used the same concentration added to the authentic and synthetic wines. The microorganism showed better growth in authentic wine, regardless of the presence of p-coumaric acid. In the case of synthetic wine, the addition of p-coumaric acid caused a delay in yeast growth and an increase in the production of volatile phenols. The coumarate decarboxylase activity did not show any difference regardless of the media and the presence of p-coumaric acid. Vinylphenol reductase showed higher activity when a higher concentration of p-coumaric acid was added in synthetic wine, but no change was observed in authentic wine.


Subject(s)
Brettanomyces/growth & development , Culture Media/metabolism , Wine/microbiology , Brettanomyces/metabolism , Coumaric Acids/metabolism , Culture Media/chemistry , Phenols/metabolism , Propionates , Wine/analysis
15.
Curr Pharm Des ; 21(2): 233-40, 2015.
Article in English | MEDLINE | ID: mdl-25163736

ABSTRACT

Safety is usually a secondary endpoint in clinical trials, and most observational studies on predictors focus on response, not toxicity. Research is clearly biased towards efficacy rather than safety, probably because of the difficulty in measuring toxicity arising from lack of standardization, low statistical power, missing data, misinterpretation, and confounding variables. An extensive search revealed very few studies on toxicity markers for the drugs used to treat rheumatoid arthritis. The literature contains many studies on predictors of the safety of methotrexate. Most analyze genetic markers, which are difficult to apply in daily practice. We found few studies on markers of toxicity for biologics. As many adverse events are related to patient characteristics, we recommend that clinicians understand the risk factors for the most common adverse events, especially infections and cancer, and manage risk on an individual basis. Moreover, patient involvement in monitoring safety is crucial.


Subject(s)
Biomarkers/metabolism , Patient Satisfaction , Antirheumatic Agents/therapeutic use , Humans
16.
Clin Exp Rheumatol ; 32(5 Suppl 85): S-163-7, 2014.
Article in English | MEDLINE | ID: mdl-25365109

ABSTRACT

Registers facilitate the collection and communication of safety concerns. There are as many different register structures as registers, making the merging of rare data and comparison between registers difficult. BIOBADASER, the Safety Register of the Spanish Society of Rheumatology has served as template for other registers within the specialty, BIOBADAMERICA, and outside rheumatology, BIOBADADERM. Here we present the limitations and strengths of such template registers.


Subject(s)
Antirheumatic Agents/therapeutic use , Biological Products/therapeutic use , Cooperative Behavior , Databases, Factual , Information Dissemination , International Cooperation , Patient Safety , Registries , Rheumatic Diseases/drug therapy , Antirheumatic Agents/adverse effects , Biological Products/adverse effects , Humans , Rheumatic Diseases/diagnosis , Risk Assessment , Risk Factors , Treatment Outcome
17.
Ann Rheum Dis ; 73(7): 1350-5, 2014 Jul.
Article in English | MEDLINE | ID: mdl-23709245

ABSTRACT

OBJECTIVES: To evaluate the validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in early spondyloarthritis (SpA) in comparison with conventional clinical measures of disease activity. METHODS: Six hundred and seventy-six incident cases of early SpA from the Esperanza programme were included. Patients were categorised into high and low disease activity states based on patient and physician global assessment scores and on the physician's decision to start treatment with a disease-modifying antirheumatic drug or tumour necrosis factor blocker. The discriminant ability of ASDAS-C-reactive protein (CRP) and ASDAS-erythrocyte sedimentation rate (ESR) was tested using standardised mean differences between patients with high and low disease activity. Convergent validity was tested by Pearson correlation between ASDAS versions and other measures of disease activity. RESULTS: ASDAS-ESR and ASDAS-CRP showed good correlation with BASDAI (r=0.79 and 0.74, respectively). Both indices correlated well with the patient global assessment (r=0.70 in both indices) and moderately with the physician global score (r=0.46 and 0.47, respectively). CRP and ESR showed poor correlation with patient- and physician-derived measures. ASDAS performed similarly across the global SpA sample, ankylosing spondylitis (AS), non-radiographic axial SpA and peripheral SpA. CONCLUSIONS: ASDAS performed as a valid activity score even being slightly better than the Bath Ankylosing Spondylitis Disease Activity Index in its ability to discriminate between high and low disease activity in early SpA. ASDAS performed similarly in AS, early forms of SpA, non-radiographic axial SpA and peripheral SpA.


Subject(s)
Spondylitis, Ankylosing/diagnosis , Adult , Back Pain/diagnosis , Blood Sedimentation , C-Reactive Protein/analysis , Early Diagnosis , Female , Humans , Male , Reproducibility of Results , Severity of Illness Index , Spondylitis, Ankylosing/blood , Spondylitis, Ankylosing/physiopathology , Surveys and Questionnaires , Time Factors
18.
Rev. esp. cir. ortop. traumatol. (Ed. impr.) ; 56(5): 393-412, sept.-oct. 2012.
Article in Spanish | IBECS | ID: ibc-103564

ABSTRACT

Con el objetivo de proponer recomendaciones para el manejo perioperatorio de los fármacos modificadores de la enfermedad (FAME) en pacientes con enfermedades reumáticas que van a ser sometidos a cirugía, se ha realizado una revisión sistemática de la literatura. Se realizó una búsqueda de todos los estudios publicados y de los resúmenes de congresos, recopilando 5.285 documentos, de los que finalmente se incluyeron 27 estudios que proporcionan información de 5.268 pacientes y 7.933 cirugías. La mayoría eran mujeres (edad media: 55 años), estaban diagnosticados de artritis reumatoide y el fármaco más estudiado fue el metotrexate (MTX). Las recomendaciones finales son las siguientes: mantener el tratamiento con MTX o leflunomida en el período perioperatorio en ausencia de otros factores de riesgo de complicaciones posquirúrgicas (Nivel de evidencia 1c; Grado de recomendación D) y con respecto a los FAME biológicos, suspenderlos momentáneamente o programar la cirugía lo más alejada posible a la última dosis, espaciando al menos 2 dosis si existieran otros factores de riesgo (Nivel de evidencia 2c; Grado de recomendación D) (AU)


The objective of this paper is make recommendations for the perioperative management of antirheumatic treatment based on the best available evidence. A systematic review was performed including studies in which patients with rheumatic diseases treated with biological and non-biological disease-modifying antirheumatic drugs (DMARDs) had undergone surgery. A total of 5,285 studies were recorded, of which 27 were finally included. These contained information on 5,268 patients and 7,933 surgeries. The majority were women (mean age 55 years) were diagnosed with rheumatoid arthritis, and the most studied drug was methotrexate (MTX). The final recommendations include: maintaining treatment with MTX or leflunomide in the perioperative period in the absence of other risk factors for postoperative complications (Level of Evidence 1c, Grade D recommendation). Biological DMARDs should be temporarily suspended, or the surgery scheduled as far as possible from the last dose, and, if there were other risk factors a space at least two doses (Level of Evidence 2c; Grade D recommendation) (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Antirheumatic Agents/therapeutic use , Perioperative Period/methods , Perioperative Period/trends , Rheumatic Diseases/epidemiology , Arthritis, Rheumatoid/diagnosis , Evidence-Based Medicine/methods , Risk Factors , Antirheumatic Agents/metabolism , Antirheumatic Agents/pharmacokinetics , Rheumatic Diseases/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...